Mitoquinone mesylate as post-exposure prophylaxis against SARS-CoV-2 infection in humans: an exploratory single center pragmatic open label non-randomized pilot clinical trial with matched controls

Chen K, Jackson NJ, Kelesidis T. Mitoquinone mesylate as post-exposure prophylaxis against SARS-CoV-2 infection in humans: an exploratory single center pragmatic open label non-randomized pilot clinical trial with matched controls. EBioMedicine. 2024 Mar 7:105042. doi: 10.1016/j.ebiom.2024.105042. Epub ahead of print. PMID: 38471990.


Related Posts

William J. Carroll, MD
Joshua N. Khalili, MD Appointed to DoM Chief Wellness Officer featured image
Sun M. Yoo, MD, MPH to Depart DoM to Pursue New Leadership Opportunity featured image